6 research outputs found
Additional file 2 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 2: Tables S2: MaxQuant software analysis of peptides detected by mass spectrometry from plasma of COVID-19 patients
Additional file 6 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 6: Table S6: Cluster analysis of proteins modulated in the plasma of COVID-19 patients
Additional file 4 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 4: Table S4: Proteins with statistically different levels in COVID-19 patients
Additional file 5 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 5: Table S5: Analysis of biological processes associated to the proteins altered in COVID-19 patients
Additional file 3 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 3: Table S3: MaxQuant software identification of proteins from plasma of COVID-19 patients
Additional file 1 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
Additional file 1: Tables S1: Demographics, clinical baseline characteristics, therapy and cause of death of COVID-19 patients